Use of histamine and related compounds to treat disorders affecting muscle function

Abstract

Described herein are compositions and methods for treating and/or preventing disorders affecting skeletal muscular function that are caused by reactive oxygen species in mammals. More specifically, the disclosure relates to the treatment and/or prevention of disorders affecting skeletal muscular function through the administration of histamine and histamine-related compounds.

1 . A method for treating a disorder affecting muscle function comprising: 
 identifying a subject with a disorder affecting muscle function; and    administering an effective amount of a compound effective to inhibit the production or release of ROS to said subject.    
     
     
         2 . The method of  claim 1 , wherein said disorder is selected from the group consisting fibromyalgia, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), primary lateral sclerosis, spinal muscular atrophy, benign focal amyotrophy, muscular dystrophies, myopathies, myositis, lupus, and metabolic diseases of the muscle.  
     
     
         3 . The method of  claim 1 , wherein said disorder is fibromyalgia.  
     
     
         4 . The method of  claim 1 , wherein said disorder is amyotrophic lateral sclerosis (ALS).  
     
     
         5 . The method of  claim 1 , wherein said disorder is multiple sclerosis (MS).  
     
     
         6 . The method of  claim 1 , wherein said compound effective to inhibit the production or release of ROS is selected from the group consisting of a compound effective to inhibit the production or release of ROS, a ROS scavenger, and combinations thereof.  
     
     
         7 . The method of  claim 6 , wherein said compound effective to inhibit the production or release of ROS is selected from the group consisting of histamine, histamine receptor agonists, histamine salts, histamine prodrugs, NADPH-oxidase inhibitors, serotonin, serotonin (5HT) receptor agonists, and substances which induce the release of an effective therapeutic amount of endogenous histamine.  
     
     
         8 . The method of  claim 6 , wherein the step of administering said ROS scavenger results in ROS scavenger-catalyzed decomposition of ROS.  
     
     
         9 . The method of  claim 6 , wherein the scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, and superoxide dismutase, or analogues thereof.  
     
     
         10 . The method of  claim 6 , wherein the scavenger is N- acetylcysteine.  
     
     
         11 . The method of  claim 6 , wherein the scavenger is selected from the group consisting of vitamin A, vitamin E, and vitamin C.  
     
     
         12 . The method of  claim 1 , wherein said compound is administered in a single dose.  
     
     
         13 . The method of  claim 1 , wherein said compound is administered in multiple doses.  
     
     
         14 . The method of  claim 1 , wherein said compound is administered at a rate of about 0.025 to about 1.0 mg/min.  
     
     
         15 . The method of  claim 1 , wherein said compound is administered over a time period of between about 1 and 30 minutes.  
     
     
         16 . The method of  claim 1 , wherein said compound is administered in a sustained release formulation.  
     
     
         17 . The method of  claim 16 , wherein said compound is administered over a time period of between about 1 and 30 days.  
     
     
         18 . The method of  claim 1 , wherein the administration of the compound is accomplished by a method selected from the group consisting of injection, intramuscular injection, intravenous injection, implantation infusion device, inhalation, and transdermal diffusion.  
     
     
         19 . The method of  claim 12 , wherein the compound is administered in a dosage of about 0.2 mg to about 100 mg.  
     
     
         20 . The method of  claim 1 , wherein said compound is administered orally.  
     
     
         21 . The method of  claim 20 , wherein said compound is in a form selected from the group consisting of capsules, tablets, granules, sprays, and syrups.  
     
     
         22 . The method of  claim 1 , further comprising the step of administering an additional compound selected from the group consisting of an anti-inflammatory drug, a pain reliever, and a muscle relaxant.  
     
     
         23 . A method for treating muscle pain associated with reactive oxygen species (ROS)-mediated oxidative damage, comprising: 
 identifying a subject with muscle pain associated with ROS-meditated oxidative damage; and    administering a compound effective to reduce the amount of ROS in said individual.    
     
     
         24 . A method for inhibiting reactive oxygen species (ROS)-mediated oxidative damage to skeletal muscles of a subject comprising: 
 identifying an individual suffering from a disorder affecting muscle function that is caused or exacerbated by ROS-mediated oxidative damage; and    administering in said individual a compound effective to reduce the amount of ROS.